IRCT20210206050259N1已完成1 期
Phase 1, safety, immunogenicity and dose finding for two strengths of 0.5 × 10^6 and 2.5 × 10^6 (TCID50) inactivated SARS-CoV-2 vaccine FAKHRAVAC (MIVAC) injected in two schedules of two doses, 2 and 3 weeks apart in healthy adults aged 18-55 years: a randomized, double blind, placebo controlled, clinical trial
Organization of Defensive Innovation and Research0 个研究点目标入组 135 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •Iranian citizenship, and residing at a distance of 40-50 km from the study center
- •The ability of participants to study and understand informed consent, preferably educational level of high school and higher
- •Age between 18 and 55 years
- •Body mass index between 18 and 35 kg/m2
- •Being healthy based on clinical and laboratory examinations
- •Temperature less than or equal to 37.2°C sublingually measured by an electronic thermometer
- •Negative IgG and IgM antibody titers against COVID-19 N antigen
- •Negative RT-PCR test for COVID-19
- •Negative ELISA test for anti-HIV IgG
- •Heart rate between 60 and 100
- •Systolic blood pressure between 90 and 140 mm Hg, diastolic blood pressure between 60 and 90 mm Hg
- •Signing informed consent
- •Accepting commitments to reduce the risk of COVID-19 infection in daily life
- •Not pregnant
- •Negative ß-hCG pregnancy test on the screening and vaccination days
- •The use of at least one safe method of contraception (condoms, oral contraceptive pills, IUD, Norplant capsule) for women of reproductive age 18 to 49 years
- •Willingness to continue using at least one safe method of contraception (condoms, oral contraceptive pills, IUD, Norplant capsule) for women of reproductive age 18 to 49 years up to three months after the second vaccine dose
- •Participants in the clinical trial should refrain from donating blood or plasma from the time of the first vaccine dose until three months after the second vaccine dose
- •should not participate in another trial during the study period
- •Expressing readiness to remain in the study for the entire study period
- •Married men should use safe methods of contraception up to three months after the second vaccine dose
排除标准
- •Any acute or chronic symptomatic disease requiring ongoing medical or surgical care at the screening day
- •Healthcare workers
- •Breastfeeding
- •History of receiving any vaccine (whether investigational or non-investigational) within 30 days prior to the screening day
- •History of receiving other investigational drugs within 60 days prior to the screening day
- •History of receiving blood or any blood product or immunoglobulin within three months prior to the screening day
- •History of Immunodeficiency disorders (suspected or definite)
- •History of long-term use of immunosuppressive drugs (more than 14 consecutive days) within four months prior to the screening day
- •History of long-term use (more than 14 consecutive days) of systemic corticosteroids (equivalent to 10 mg or more daily prednisolone) or high-dose inhaled steroids (more than 800 µg/day of beclomethasone dipropionate or equivalent) within four months prior to the screening day (excluding topical steroids)
- •History of allergic diseases such as angioedema or anaphylaxis
- •History of any known allergy to drugs or vaccines including aluminum phosphate and albumin
- •History of known allergy to eggs
- •History of autoimmune diseases
- •Chemotherapy or radiotherapy in the last 5 years
- •History of cancer in the last 5 years
- •History of serious psychiatric illnesses
- •History of blood disorders (dyscrasia, coagulation disorders, platelet deficiency or disorder, deficiency of blood factors)
- •History of chronic obstructive pulmonary disease such as asthma diagnosed by a specialist
- •History of ischemic heart disease currently treated by a cardiologist or receiving any cardiac interventions
- •History of hypertension currently treated by a physician
- •History of diabetes currently treated by a physician
- •Congenital anomalies, growth retardation, genetic defects or severe malnutrition
- •Individual or family history of chronic neurological diseases (including seizures and epilepsy)
- •History of thyroid disease or Thyroidectomy
- •Any history of substance or alcohol abuse in the past 2 years
- •Abnormal hematological or biochemical test results at the time of screening
- •History of confirmed COVID-19
- •Acute febrile illness at the time of vaccination
- •History of allergy to acetaminophen
- •History of acute or chronic hepatitis B and C
- •History of pulmonary or extrapulmonary tuberculosis or receiving antituberculotic treatment
- •Receiving tuberculosis prophylaxis
- •History of faint in any encounter with needles or phlebectomy
- •Splenectomy for any reason or history of abnormal spleen function
- •Any close contact with a confirmed COVID-19 case up to two weeks before receiving the first vaccine dose
- •Previous history of diseases such as SARS and MERS
- •Not fit to participate in the trial (the decision is at the discretion of the chief investigator)
- •People who are currently serving their obligatory military service in the Armed Forces
研究者
相似试验
进行中（未招募）
1 期
Phase I vaccine study of pEVAC-PS coronavirus vaccineISRCTN87813400niversity Hospital Southampton NHS Foundation Trust39
已完成
1 期
Study to evaluate safety and possible adverse reactions, especially serious, with a vaccine for measles and rubella in healthy subjects.Measles and RubellaRBR-9hckj4Bio-Manguinhos/Fiocruz/MS
招募中
不适用
A Phase I trial to assess safety and immunogenicity of i.d. DNA priming and i.m. MVA boosting in healthy volunteers in MozambiqueHIV/AIDSPACTR201106000304583Swedish Institute for Infectious Disease Control24
进行中（未招募）
1 期
A study of a new vaccine against Marburg virus in adults aged 18–55 yearsMarburg virus disease (MVD)Infections and InfestationsISRCTN97679658niversity of Oxford66
招募中
1 期
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9Influenza prophylaxisCTIS2022-500706-18-01Oslo University Hospital Hf30